COMBINATORIAL CHEMISTRY TO DISCOVER NOVEL SWEETENERS

描述：(改编自申请人的摘要)非小说 多种加工食品中的致龋剂和无热量甜味剂 而饮料产品则等待着未来的发现。这样的甜味剂会 对糖的市场和预防有巨大的影响- 相关疾病，如龋齿和糖尿病。对病人来说 在控制饮食碳水化合物摄入量的情况下，好的理由是- 品尝合成甜味剂是显而易见的。这个第一阶段的STTR项目将 评估针对甜胍的单抗作用的能力 筛选可能具有以下功能的化合物的组合模拟肽文库 具有甜味剂活性。部署了一种基于抗体的 发现新型甜味化合物的“人工受体”是 这是这个项目独一无二的。 该项目有三个里程碑：(1)开发有偏组合 利用单抗鉴定新配体的模拟多肽文库 抗甜味剂抗体：(2)荧光偏振免疫分析 识别模拟多肽配体；(3)“二次迭代”的产生 有偏向的候选化合物文库，以供进一步表征。 每个里程碑都将由申请者独立完成 然而，组织或研究组织的成功 项目需要双方的合作和伙伴关系。这个 这项STTR提案的目标与计划高度相关 美国国立卫生研究院龋齿、营养和氟化物项目 牙科研究(NIDR)和国家牙科研究所的使命 糖尿病、消化和肾脏疾病(NIDDK)。 建议的商业应用：不可用

DESCRIPTION: (Adapted from the applicant's abstract) Novel non- cariogenic and non-caloric sweeteners for a variety of processed food and beverage products await future discoveries. Such sweeteners will have a dramatic impact on the marketplace and prevention of sugar- associated diseases, such as dental caries and diabetes. For patients with regulated dietary carbohydrate intake, the rationale for good- tasting synthetic sweeteners is obvious. This Phase I STTR Project will assess the ability of monoclonal antibodies made to sweet guanidines to screen combinatorial peptidomimetic libraries of compounds that may possess sweetener activity. The deployment of an antibody-based "Artificial Receptor" for the discovery of novel sweet compounds is unique to this project. The project has three milestones: (1) Develop biased combinatorial peptidomimetic libraries to identify novel ligands using monoclonal anti-sweetener antibodies: (2) Fluorescence polarization immunoassays to identify peptidomimetic ligands; (3) Generation of "second-iteration" biased libraries of candidate compounds for further characterization. Each Milestone will be carried out independently by the applicant organization or the research organization, however, the success of the project requires cooperation and partnership between both parties. The objective of this STTR proposal has high program relevance to the Caries, Nutrition and Fluoride Program of the National Institute of Dental Research (NIDR) and the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE